-
Talk to Us: info@nidccglobal.org
-
Location: Washington, DC | Abuja, Nigeria
Language:
Everyday Economic News
Ticketplus, Live Event Ticketing Platform, Files for NYSE American IPO
Ticketplus, a live event ticketing platform operating across Latin America, has filed for an Initial Public Offering (IPO) on NYSE American under the ticker "TP." The company plans to offer 1,875,000 ordinary shares at $8.00 each, aiming to raise $15.0 million to fund platform development, international expansion, acquisitions, and marketing. Ticketplus utilizes a full-operations model in Chile and a white-label SaaS model elsewhere, supporting event discovery, ticketing, payments, and analytics.
U.S. Stocks Move | Ticketplus Ltd (TP.US) Debuts on U.S. Market, Drops Over 15% After Opening
Ticketplus Ltd (TP.US) made its debut on the U.S. stock market. However, the stock experienced a significant drop of over 15% immediately after its opening.
US Stocks Movement | Ticketplus Ltd (TP.US) debuts on the US stock market, falling over 15% after the opening
Ticketplus Ltd (TP.US), a technology firm focused on the Latin American live entertainment industry, debuted on the US stock market, with its stock falling over 15% to $6.771 after opening. Founded in 2014 and headquartered in Santiago, Chile, Ticketplus operates in 11 countries, providing a full-stack event management platform for concerts, sports events, and exhibitions. The company has expanded internationally and uses AI and automation to enhance ticketing operations and risk control.
Bill Ackman’s Pershing Square Dual IPO Priced At $5B To Hit NYSE Today: Here’s What You Should Know
Bill Ackman's Pershing Square USA Ltd. (PSUS) and Pershing Square Inc. (PS) are expected to begin trading on the NYSE today, after pricing their dual IPOs at $5 billion. The offering includes $2.8 billion already committed by large investors, though it falls short of an initial $10 billion ambition. This marks a renewed effort by Ackman after a previous attempt in 2024 was withdrawn due to weak investor interest.
Parabilis Medicines, Inc. - Common Stock (Nasdaq:PBLS) Stock Quote
This article provides a stock quote and related news for Parabilis Medicines, Inc. (PBLS). It includes current trading information, performance data, and recent news headlines highlighting the company's IPO success and insider stock purchases, indicating significant interest and investment in the biotech firm.
SpaceX IPO Fever Sends NASA ETF To Record AUM – One Holding Could 'Dominate' The Space Race, Says Analyst
The Tema Space Innovators ETF (NASA) has reached a record $2.6 billion in assets under management, driven by retail investor excitement surrounding SpaceX's anticipated $1.8 trillion IPO. While SpaceX is the ETF's second-largest holding, Oppenheimer analysts believe Iridium Communications (IRDM) could be a significant beneficiary of the expanding space economy, raising its price target for IRDM due to its role in the ecosystem being built around SpaceX's growing launch capacity, Starlink, and AI communication infrastructure.
Latigo IPO raises nearly $350M for pain drug development
Latigo Biotherapeutics has successfully raised nearly $350 million through its initial public offering to advance the development of non-opioid pain medications. This IPO marks a significant uptick in large biotech IPOs this year, signaling renewed investor confidence in the sector. Latigo aims to compete with larger pharmaceutical companies like Vertex and Eli Lilly in the burgeoning market for ion-channel-blocking pain drugs, particularly for acute and chronic pain conditions.
Latham & Watkins Advises on Latigo Biotherapeutics’ Upsized US$345.6 Million Initial Public Offering
Latham & Watkins LLP represented the underwriters in Latigo Biotherapeutics' upsized initial public offering, which raised US$345.6 million. Latigo, a clinical-stage biopharmaceutical company, offered 19,200,000 shares at US$18 each, with an additional option for underwriters to purchase more shares. The Latham & Watkins Capital Markets team was led by New York partners Nathan Ajiashvili, Sandy Kugbei, and Alison Haggerty.
Latigo Biotherapeutics, Clinical-Stage Developer of Selective Nav1.8 Non‑Opioid Pain Medicines for Acute and Chronic Pain, Files for Nasdaq Global Select Market IPO
Latigo Biotherapeutics, a clinical-stage biopharmaceutical company focused on non-opioid pain medicines, has filed for an IPO on the Nasdaq Global Select Market under the symbol LTGO. The company priced its IPO at $18.00 per share, selling 19,200,000 shares for gross proceeds of approximately $345.6 million. Proceeds will fund late-stage clinical trials for its lead Nav1.8 inhibitor LTG-001 for acute pain and its chronic pain candidate LTG-321, with significant milestones expected in late 2027.
Liftoff Mobile (LFTO) Ellis Trust discloses 5.9% ownership stake post-IPO
The Ellis Trust, with Mark E. Ellis and Sydney L. Ellis as co-trustees, has reported a 5.9% beneficial ownership stake in Liftoff Mobile (LFTO) post its initial public offering. This ownership amounts to 9,939,671 shares of common stock, representing 5.9% of the 169,330,527 outstanding shares after the IPO and full exercise of the underwriters' over-allotment option. The Schedule 13G filing indicates shared voting and dispositive power over these shares by the co-trustees.